A Phase IV Interventional Post Approval Trial to Assess the Safety of Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (DME) in Patients in India.
Latest Information Update: 08 May 2024
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Acronyms VISION-AF
- Sponsors Bayer
- 26 May 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2023 Planned End Date changed from 30 Aug 2024 to 30 Apr 2024.
- 03 Mar 2023 Planned primary completion date changed from 30 Aug 2024 to 30 Apr 2024.